Shares of Moderna rose 4.89% to $121.95 at 09:55 EST on Thursday, following last session’s downward trend. NASDAQ Composite is sliding 0.61% to $12,740.79, following last session’s downward trend, This seems, up to now, a somewhat rough trend trading session today.
Moderna’s last close was $109.18, 46.37% below its 52-week high of $178.50.
Moderna’s sales growth is 1876.9% for the ongoing quarter and 19117.5% for the next. The company’s growth estimates for the current quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a negative 2.34%, a negative 0.40%, and a negative 1.81%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 7.26%, 9.20%, and 8.69%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $121.95 at 09:55 EST, way under its 52-week high of $178.50 and way higher than its 52-week low of $17.76.
Moderna’s Moving Average
Moderna’s worth is under its 50-day moving average of $129.00 and way higher than its 200-day moving average of $84.67.
Previous days news about Moderna
Moderna expects to deliver 100 million doses of its Covid-19 vaccine in the U.S. in Q1. According to MarketWatch on Monday, 4 January, "That is the equivalent of 50 million vaccinations as the Moderna vaccine requires two doses. ", "Globally, Moderna plans to deliver an estimated 500 to 600 million doses in 2021. "
Moderna expects to deliver 100 million vaccine doses in U.S. in first quarter. According to MarketWatch on Monday, 4 January, "Shares of Moderna Inc. gained 0.4% in trading on Monday after the biotechnology company said it plans to produce 100 million doses of its COVID-19 vaccine in the first quarter for the U.S. market. ", "Globally, Moderna plans to deliver an estimated 500 to 600 million doses in 2021. "
Moderna lifts vaccine output outlook 20% to at least 600 million. According to Bloomberg Quint on Monday, 4 January, "The U.S. has ordered 200 million doses of the vaccine, with options for buying 300 million more, and Moderna confirmed in the statement that it still expects to deliver all 200 million doses by the end of the second quarter.", "That puts Moderna roughly in line with its goal of delivering approximately 20 million doses to the U.S. last year."
Stocks making the biggest moves in the premarket: Micron Technology, first solar, Moderna & more. According to CNBC on Tuesday, 5 January, "Moderna (MRNA) – Moderna received approval for its Covid-19 vaccine from Israeli health regulators. "
Moderna covid vaccine wins EU backing in struggle to stem virus. According to Bloomberg Quint on Wednesday, 6 January, "Germany expects to get more than 130 million doses of vaccine once the Moderna and BioNTech shots are shipped, he said — enough to inoculate 65 million people, or about three-quarters of the population.", "The Moderna vaccine warded off Covid-19 in 94% of volunteers in a large clinical trial. "
Moderna shares gain at opening bell as vaccine wins EU medical regulator's OK. According to MarketWatch on Wednesday, 6 January, "The COVID-19 vaccine developed by Moderna has been cleared by the European Union’s medical regulator, paving the way for the vaccine to be rolled out in the 27-member bloc.", "Also read: Moderna expects to deliver 100 million doses of its COVID-19 vaccine in the U.S. in Q1"
Covid-19 vaccine update – EMA recommends Moderna inc. vaccine.. According to FX Empire on Wednesday, 6 January, "Once the EU Commission has granted conditional marketing authorization for the vaccine, Moderna Inc. can begin to distribute the vaccine across the region.", "Today, the EMA’s human medicines Committee ("CHMP") recommended the COVID-19 Moderna Inc. vaccine for authorization."
Moderna gets EU approval; allergic reactions rare: virus update. According to Bloomberg Quint on Wednesday, 6 January, "About 5.2 million doses of Covid-19 vaccines from Pfizer Inc.-BioNTech SE and Moderna Inc. have been administered in the U.S. since mid-December, according to data compiled by Bloomberg News. ", "Operation Warp Speed has achieved that goal with vaccines from Pfizer Inc. and Moderna Inc. authorized for emergency use, along with antibody therapies available to treat Covid-19 cases."